A small clinical trial of a once-failed Alzheimer’s drug offered tantalizing but inconclusive hints of benefit, propelling shares in its biotech maker higher by more …
After numerous setbacks in Alzheimer’s disease, Lilly has high hopes for a breakthrough with donanemab. When the FDA controversially approved Biogen’s Aduhelm in June, it …
The U.S. health department’s inspector general will review how the Food and Drug Administration grants accelerated approvals of new drugs, announcing a broad investigation Wednesday …
